Valuation: Evaxion A/S

Market Cap 27.36M 24.3M 22.72M 20.71M 38.98M 2.63B 39.52M 275M 106M 1.34B 103M 100M 4.31B P/E 2026 *
-82x
P/E 2027 * -219x
Enterprise Value 27.36M 24.3M 22.72M 20.71M 38.98M 2.63B 39.52M 275M 106M 1.34B 103M 100M 4.31B EV / Sales 2026 *
-
EV / Sales 2027 * 5.86x
Free-Float
58.26%
Yield 2026 *
-
Yield 2027 * -
1 day-3.05%
1 week-2.45%
Current month-3.05%
1 month+6.71%
3 months-0.62%
6 months-19.29%
Current year-33.33%
1 week 3.13
Extreme 3.13
3.35
1 month 2.99
Extreme 2.99
3.35
Current year 2.77
Extreme 2.77
5.48
1 year 2.77
Extreme 2.77
12.15
3 years 1.2
Extreme 1.2
68.05
5 years 1.2
Extreme 1.2
1,252
10 years 1.2
Extreme 1.2
1,252
Manager TitleAgeSince
Chief Executive Officer 59 24/11/2025
Corporate Officer/Principal 49 11/08/2008
Director of Finance/CFO 53 01/11/2024
Director TitleAgeSince
Chairman 58 25/11/2020
Director/Board Member 56 01/01/2018
Director/Board Member 68 25/05/2021
Date Insider Type Main position Quantity % Market Cap. Importance
16/4/26 Other

Director

2,376 0.0006%
18/3/26 Other

Chief Financial Officer

645,750 0.1549%
18/3/26 OtherCompany 360,406 0.0864%
Change 5-day change 1-year change 3-year change Capi.($)
-3.05%-2.45%-28.38%-92.60% 27.36M
+4.16%-0.36%+49.37%+94.17% 74.46B
-0.61%+0.69%+36.36%+82.72% 60.14B
-2.54%-0.21%+6.34%+31.72% 48.15B
-3.02%-5.20%+27.94%+34.47% 44.25B
+0.31%+3.02%+348.95%+686.74% 43.99B
-1.96%-0.33%+7.04%+100.99% 41.61B
+3.32%+3.49%+11.18%+51.23% 29.97B
+4.77%+6.16%+36.77%+22.78% 29.31B
-4.86%-10.66%-26.27%+328.03% 24.93B
Average -0.34%+1.77%+46.93%+134.03% 39.68B
Weighted average by Cap. +0.18%+1.83%+59.99%+150.77%

Financials

2026 *2027 *
Net sales - 4.67M 4.15M 3.88M 3.54M 6.66M 450M 6.75M 46.93M 18.17M 229M 17.53M 17.15M 736M
Net income -15.56M -13.82M -12.93M -11.78M -22.17M -1.5B -22.48M -156M -60.53M -763M -58.42M -57.16M -2.45B -11.81M -10.49M -9.81M -8.94M -16.83M -1.14B -17.07M -119M -45.95M -579M -44.35M -43.39M -1.86B
Net Debt - -
Logo Evaxion A/S
Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Employees
46
Date Price Change Volume
02/10/26 US$3.180 -3.05% 38,119
30/09/26 US$3.280 +0.31% 18,053
29/09/26 US$3.270 +0.93% 38,135
28/09/26 US$3.240 -2.99% 55,694
25/09/26 US$3.340 +2.45% 45,056
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.280USD
Average target price
11.25USD
Spread / Average Target
+242.99%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EVAX Stock